Enovis (ENOV)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
$19.03-4.75%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-09
Broken: Primary pillar broken — Adjusted EBITDA near $430 million: FY26 EBITDA guidance $425M-$435M (mid $430M) vs target $425M-$435M.
Enovis grows revenue about 5% a year to $2.34 billion in 2026. Profit rises with adjusted EBITDA near $430 million. Innovation in orthopedics helps keep sales strong. The company stays on track with management goals.
Sales growth could slow below 5%. Profit margins might shrink. Innovation may not keep up with competitors.
The price is about 56% below our fair value near $58. Analysts expect about 5.5% revenue growth. We agree with this growth but see upside if innovation succeeds.
Breaks if: Adjusted EBITDA falls below $425 million in FY26
Sustain full-year 2026 adjusted EBITDA guidance in the range of $425-435 million.
Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA guidance for 2026 is maintained at $425-435 million, up from 2025 actuals near $400 million. This reflects management's focus on improving profitability. The trajectory shows progress with stable and increased guidance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround story in the healthcare sector. ENOV is currently navigating through a period of mixed performance, with strong recent results but ongoing risks that could impact future growth.
The market seems to have priced in a low expectations gap, indicating that investors are cautious about ENOV's future performance. Valuation is considered cheap compared to peers, suggesting that there may be room for improvement if the company meets its guidance.
Management has reaffirmed revenue and adjusted EBITDA guidance, indicating a focus on maintaining growth and profitability. However, the company has a history of earnings misses, which introduces some risk to its near-term performance.
The thesis hinges on management's ability to execute on its guidance and the overall health of the healthcare sector. Key factors include the performance of sector leaders and broader economic indicators, such as job reports.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Enovis guided for a 100 basis point decline in EBITDA margins next year. This is due to the planned acquisition of Amplitude Surgical, which may strain resources. The company also experienced a sharp drop in stock price, indicating a potential repricing of the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Adjusted EBITDA is expected to be in a range of $425-435 million.”
“Adjusted EBITDA is expected to be in a range of $425-435 million.”
“Adjusted EBITDA is forecasted to be $395-405 million, as compared to the prior outlook of $392-402 million.”
Breaks if: Innovation efforts stall or fail to advance orthopedics products
Drive growth through enhanced commercial execution and strengthening the innovation pipeline.
Stated as a priority in 3 of last 3 quarters. Enovis reported organic sales growth of 5% in 2026-Q2 and 3% in 2026-Q1, with reconstructive sales growing 6-11% organically. Management emphasizes commercial execution and innovation as key drivers. The trajectory shows delivering growth aligned with stated priorities.
“Commercial execution is improving, our innovation pipeline continues to strengthen our competitive positioning.”
“Growth in the quarter was supported by contributions from recent product launches which enhance our competitive positioning and expand our addressable market.”
“We advanced our second-year Lima integration priorities and continued to demonstrate above-market organic growth with sustainable year-over-year operating improvements.”
Breaks if: Revenue falls below $2.31 billion in FY26
Maintain full-year 2026 revenue guidance targeting $2.31-2.37 billion with 4-6% organic growth.
Stated as a priority in 3 of last 3 quarters. Revenue guidance for 2026 is reaffirmed at $2.31-2.37 billion, reflecting 4-6% organic growth. This follows 2025 actual revenue of approximately $2.25 billion, showing consistent growth expectations. The trajectory is delivering as management maintains stable guidance.
“Enovis reaffirmed financial expectations for 2026. Revenue is expected to be in a range of $2.31-2.37 billion.”
“Enovis reaffirms financial expectations for 2026. Revenue is expected to approximate $2.31-2.37 billion.”
“Revenue is expected to be in the range of $2.24-2.27 billion, versus prior expectations of $2.245-2.275 billion.”
In the next 1-3 years, ENOV's performance will depend on its ability to navigate risks while capitalizing on sector momentum. Not investment advice.